Compare NEWT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEWT | CLLS |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | France |
| Employees | 572 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.6M | 394.4M |
| IPO Year | N/A | 2014 |
| Metric | NEWT | CLLS |
|---|---|---|
| Price | $13.75 | $3.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $15.33 | $8.33 |
| AVG Volume (30 Days) | ★ 125.0K | 30.6K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | $0.98 |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $1.33 |
| 52 Week High | $14.91 | $5.48 |
| Indicator | NEWT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.86 | 39.24 |
| Support Level | $12.56 | $3.05 |
| Resistance Level | $14.21 | $3.35 |
| Average True Range (ATR) | 0.42 | 0.17 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 74.06 | 32.25 |
NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.